Unlock stock picks and a broker-level newsfeed that powers Wall Street.

Buenos Aires - Delayed Quote ARS

Bioceres Crop Solutions Corp. (BIOX.BA)

5,180.00
+150.00
+(2.98%)
At close: April 24 at 4:56:17 PM GMT-3
Loading Chart for BIOX.BA
  • Previous Close 5,030.00
  • Open 5,100.00
  • Bid 5,160.00 x --
  • Ask 5,240.00 x --
  • Day's Range 5,030.00 - 5,270.00
  • 52 Week Range 3,196.00 - 5,270.00
  • Volume 21,481
  • Avg. Volume 5,460
  • Market Cap (intraday) --
  • Beta (5Y Monthly) 0.60
  • PE Ratio (TTM) --
  • EPS (TTM) -4.67
  • Earnings Date Feb 11, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Bioceres Crop Solutions Corp., together with its subsidiaries, provides crop productivity solutions. It operates through Seed and Integrated Products, Crop Protection, and Crop Nutrition segments. The Seed and Integrated Products segment provides seed traits, germplasms, and seed treatment packs for healthier, and higher yielding crops. The Crop Protection segment develops, produces, and markets Rizoderma, adjuvants, therapies, herbicides, insecticides, fungicides, and baits. The Crop Nutrition segment develops, produces, commercializes, and sells inoculants, bio-inductors, and biological and microgranulated fertilizers. It also offers HB4, a drought tolerant seed technology program. The company operates in Argentina, Brazil, North America, Europe, the Middle East, South America, the United States, and internationally. Bioceres Crop Solutions Corp. was founded in 2001 and is headquartered in Rosario, Argentina.

investors.biocerescrops.com/home/default.aspx

--

Full Time Employees

June 30

Fiscal Year Ends

Recent News: BIOX.BA

View More

Compare To: BIOX.BA

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: BIOX.BA

View More

Valuation Measures

Annual
As of 4/23/2025
  • Market Cap

    282.06B

  • Enterprise Value

    562.72B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.37%

  • Return on Assets (ttm)

    2.47%

  • Return on Equity (ttm)

    0.62%

  • Revenue (ttm)

    407.73M

  • Net Income Avi to Common (ttm)

    1.5M

  • Diluted EPS (ttm)

    -4.67

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    31.2M

  • Total Debt/Equity (mrq)

    82.48%

  • Levered Free Cash Flow (ttm)

    -22.36M

Research Analysis: BIOX.BA

View More

Company Insights: BIOX.BA

Research Reports: BIOX.BA

View More

People Also Watch